140 related articles for article (PubMed ID: 31322734)
1. Prevention of transfusion-transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation.
Shigemura T; Yanagisawa R; Komori K; Morita D; Kurata T; Tanaka M; Sakashita K; Nakazawa Y
Transfusion; 2019 Oct; 59(10):3065-3070. PubMed ID: 31322734
[TBL] [Abstract][Full Text] [Related]
2. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
Hall S; Danby R; Osman H; Peniket A; Rocha V; Craddock C; Murphy M; Chaganti S
Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
[TBL] [Abstract][Full Text] [Related]
3. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
[TBL] [Abstract][Full Text] [Related]
4. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients.
Narvios AB; de Lima M; Shah H; Lichtiger B
Bone Marrow Transplant; 2005 Sep; 36(6):499-501. PubMed ID: 16044143
[TBL] [Abstract][Full Text] [Related]
5. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
[TBL] [Abstract][Full Text] [Related]
6. Prevention of transfusion-transmitted cytomegalovirus in low-birth weight infants (≤1500 g) using cytomegalovirus-seronegative and leukoreduced transfusions.
Josephson CD; Castillejo MI; Caliendo AM; Waller EK; Zimring J; Easley KA; Kutner M; Hillyer CD; Roback JD
Transfus Med Rev; 2011 Apr; 25(2):125-32. PubMed ID: 21345642
[TBL] [Abstract][Full Text] [Related]
7. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
8. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
Nichols WG; Price TH; Gooley T; Corey L; Boeckh M
Blood; 2003 May; 101(10):4195-200. PubMed ID: 12531791
[TBL] [Abstract][Full Text] [Related]
9. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
[TBL] [Abstract][Full Text] [Related]
10. Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single-institute experience in Japan.
Tomonari A; Takahashi S; Ooi J; Tsukada N; Konuma T; Kato S; Kasahara S; Iseki T; Yamaguchi T; Tojo A; Asano S
Eur J Haematol; 2008 Mar; 80(3):251-7. PubMed ID: 18081702
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs.
Mabilangan C; Burton C; Nahirniak S; O'Brien S; Preiksaitis J
Am J Transplant; 2020 Dec; 20(12):3509-3519. PubMed ID: 32428296
[TBL] [Abstract][Full Text] [Related]
12. Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy.
Delaney M; Mayock D; Knezevic A; Norby-Slycord C; Kleine E; Patel R; Easley K; Josephson C
Transfusion; 2016 Aug; 56(8):1945-50. PubMed ID: 27080192
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infections in unrelated cord blood transplantation in pediatric patients: incidence, risk factors, and outcomes.
Al-Hajjar S; Al Seraihi A; Al Muhsen S; Ayas M; Al Jumaah S; Al Jefri A; Shoukri M; El Solh H
Hematol Oncol Stem Cell Ther; 2011; 4(2):67-72. PubMed ID: 21727767
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.
Ljungman P; Larsson K; Kumlien G; Aschan J; Barkholt L; Gustafsson-Jernberg A; Lewensohn-Fuchs I; Ringdén O
Scand J Infect Dis; 2002; 34(5):347-50. PubMed ID: 12069017
[TBL] [Abstract][Full Text] [Related]
15. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis.
Mainou M; Alahdab F; Tobian AA; Asi N; Mohammed K; Murad MH; Grossman BJ
Transfusion; 2016 Jun; 56(6 Pt 2):1569-80. PubMed ID: 26826015
[TBL] [Abstract][Full Text] [Related]
17. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
18. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study.
Preiksaitis JK; Desai S; Vaudry W; Roberts S; Akabutu J; Grundy P; Wilson B; Boshkov L; Hannon J; Joffres M
Transfusion; 1997 Sep; 37(9):941-6. PubMed ID: 9308642
[TBL] [Abstract][Full Text] [Related]
19. A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients.
Hill JA; Pergam SA; Cox E; Xie H; Leisenring WM; Boeckh M; Delaney C; Milano F
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2094-2100. PubMed ID: 29753836
[TBL] [Abstract][Full Text] [Related]
20. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
